- Mitchell S. Steiner, M.D., Chief Executive Officer
- Marc S. Hanover, President, Chief Operating Officer
- Mark. E. Mosteller, Vice President, Chief Financial Officer
- Henry P. Doggrell, Vice President, General Counsel
- Ronald A. Morton, Jr., M.D., Vice President, Chief Medical Officer
- James T. Dalton, Ph.D., Vice President, Preclinical Research and Development
- K. Gary Barnette, Ph.D., Vice President, Clinical Research and Development Strategy
- Michael D. Brown, Vice President, Marketing and Managed Care
- Greg Deener, Vice President, Sales and Marketing
- Shontelle Dodson, PharmD, Vice President, Medical Affairs
- Jeff Hesselberg, Vice President, Regulatory Affairs
- Domingo Rodriguez, M.D., Vice President, Clinical Operations
- Christopher West, Vice President, Sales
Mitchell S. Steiner, M.D., F.A.C.S., Chief Executive Officer and Vice Chairman of our Board of Directors. Dr. Steiner, a co-founder of GTx, has served as our Chief Executive Officer and Vice Chairman of our Board of Directors since the company's inception in September 1997. From 1995 to 2003, Dr. Steiner held numerous academic appointments, including Chairman and Professor of Urology, Director of Urologic Oncology and Research and the Chair of Excellence in Urologic Oncology at the University of Tennessee. Since 2003, Dr. Steiner has continued to serve on the faculty at the University of Tennessee. Dr. Steiner holds a B.A. in Molecular Biology from Vanderbilt University, an M.D. from the University of Tennessee and performed his surgery and urologic training at The Johns Hopkins Hospital.
Marc S. Hanover, President and Chief Operating Officer. Mr. Hanover, a co-founder of GTx, has served as our President and Chief Operating Officer and as a director since the company's inception in September 1997. Prior to joining GTx, Mr. Hanover was a founder of Equity Partners International, Inc., a private equity firm in Memphis, Tennessee, and participated as a founder and investor in three healthcare companies. From 1985 to 1997, Mr. Hanover was a Senior Vice President and a member of the Executive Management Committee of National Bank of Commerce in Memphis, Tennessee. Mr. Hanover holds a B.S. in Biology from the University of Memphis and an MBA in Finance from the University of Memphis.
Mark E. Mosteller, CPA, Vice President, Chief Financial Officer. Mr. Mosteller has served as our Chief Financial Officer since August 2001 and was appointed Vice President and Treasurer on January 20, 2005. From April 1997 to August 2001, Mr. Mosteller was an Executive Vice President of Union Planters Bank National Association (a subsidiary of Union Planters Corporation), a bank holding company and Chief Operating Officer of Union Planters Mortgage, the mortgage division of Union Planters Bank National Association. From 1994 to 1997, Mr. Mosteller was the Chief Financial Officer of Boatmen's National Mortgage, Inc., the mortgage subsidiary of Boatmen's Bancshares, Inc. From 1984 to 1994, Mr. Mosteller was employed as an audit senior manager with Ernst & Young LLP. Mr. Mosteller is a Certified Public Accountant and holds a B.S. in Accounting from the University of Tennessee.
Henry P. Doggrell, Vice President, General Counsel and Secretary. Mr. Doggrell has served as our General Counsel and Secretary since October 2001 and was appointed Vice President on January 20, 2005. From April 1998 to August 2001, Mr. Doggrell was Senior Vice President, Corporate Affairs at Buckeye Technologies, Inc., a specialty cellulose company, where he was responsible for matters including corporate finance, investor relations, mergers and acquisitions, intellectual property and licensing and strategic development. From 1996 to 1998, Mr. Doggrell served as General Counsel and Secretary of Buckeye Technologies. Prior to joining Buckeye Technologies, Mr. Doggrell was a partner of the Baker, Donelson, Bearman, Caldwell & Berkowitz law firm from 1988 to 1996, where he served as a member of the law firm management committee and Chair of the firm's Corporate Securities department. Mr. Doggrell holds a B.S. in Commerce from the University of Virginia and a J.D. from Vanderbilt University.
Ronald A. Morton, Jr., M.D., F.A.C.S., Vice President, Chief Medical Officer. Dr. Morton has served as Chief Medical Officer of GTx since April 2007. Dr. Morton joined GTx from the University of Medicine & Dentistry of New Jersey Robert Wood Johnson Medical School, where he served as Professor of Surgery, Chief of Urology and Director of Urologic Oncology for the Cancer Institute of New Jersey. Dr. Morton also held the Conzen Chair for Clinical Research and was the Director of the New Jersey Center for Clinical and Translational Sciences. Prior to joining Robert Wood Johnson Medical School in 2004, Dr. Morton held a dual faculty appointment at the Baylor College of Medicine in the Scott Department of Urology and in the Department of Molecular and Cell Biology, was Clinical Director of the Baylor Adult Urology Program, Chief of Urology at the Houston Veterans Administration Medical Center and Director of the Baylor Prostate Cancer Center Research Laboratories. He received his bachelor and medical degrees from the Johns Hopkins University and completed his urology training and postdoctoral fellowship and was an AFUD Scholar at the Johns Hopkins Brady Urological Institute.
James T. Dalton, Ph.D., Vice President, Preclinical Research and Development. Dr. Dalton has served as Vice President, Preclinical Research and Development since January 2005. Dr. Dalton served as a scientific consultant to GTx from 1999 to 2005. Prior to joining GTx, Dr. Dalton held several academic appointments, including Assistant and Associate Professor of Pharmaceutical Sciences in the College of Pharmacy at the University of Tennessee, Memphis (1992-2000) and Professor and Chair of the Division of Pharmaceutics, College of Pharmacy at The Ohio State University. SARMs were first discovered in Dr. Dalton’s research laboratories, and he is co-inventor on all SARM patents. Dr. Dalton holds a B.S. in Pharmacy from the University of Cincinnati and a Ph.D. in Pharmaceutics and Pharmaceutical Chemistry from The Ohio State University.
K. Gary Barnette, Ph.D., Vice President, Clinical Research and Development Strategy. Dr. Barnette was appointed Vice President, Clinical Research and Development Strategy in November 2005, and prior to that he served as Vice President, Clinical Research and Development since January 20, 2005. He also served as the company's Director of Regulatory Affairs since December 2001. From May 1998 to December 2001, Dr. Barnette was Assistant Director and then Director, Regulatory Affairs at Solvay Pharmaceuticals, Inc., a specialty pharmaceutical company. From March 1995 to May 1998, Dr. Barnette was a Clinical Pharmacology and Biopharmaceutics Reviewer at the FDA, where he reviewed in the Divisions of Reproductive and Urologic Drug Products, Metabolic and Endocrine Drug Products and Gastrointestinal and Coagulation Drug Products. Dr. Barnette holds a B.S. in Biology from Salem College and a Ph.D. in Basic Pharmaceutical Sciences from West Virginia University.
Michael D. Brown, Vice President, Marketing and Managed Care. Mr. Brown was appointed Vice President, Marketing and Managed Care in 2008. Mr. Brown has over 15 years of experience in pharmaceutical sales and marketing with GlaxoSmithKline plc; most recently as Regional Vice President, Managed Markets, where he was responsible for all managed care initiatives in a six state region. He also has experience launching multiple large pharmaceutical products in the areas of bone health and urology. Mr. Brown holds a B.S. in International Marketing from Arizona State University.
Greg Deener, Vice President, Sales and Marketing. Mr. Deener was appointed Vice President, Sales and Marketing on January 20, 2005, and prior to that he served as our Director of Marketing and Sales since February 2004. Mr. Deener has over 20 years of experience in Marketing and Sales and has launched a urology medicine within the U.S. From 1996 to December 2003, Mr. Deener served as a Marketing Director for GlaxoSmithKline plc in various roles within the U.S. and Europe. Most recently, Mr. Deener was responsible for the launch of Avodart, a urology medicine for BPH. From 1983 to 1996, Mr. Deener worked for Procter & Gamble in Brand Management and Sales. Mr. Deener holds a B.S. in Business Administration from the University of North Carolina at Chapel Hill.
Shontelle Dodson, PharmD, Vice President, Medical Affairs. Dr. Dodson was appointed Vice President, Medical Affairs in 2008. Dr. Dodson has over 13 years of pharmaceutical experience, most recently at Pfizer, Inc., where she served as Senior Director and Group Leader, Global Medical, heading up the field-based medical organization for the Urology and Respiratory franchise. Earlier, she was Director, Team Leader, US Medical, leading the Viagra® medical team and the U.S. field-based medical effort supporting the company’s urology and sexual health medicines with total product sales exceeding $1.8 billion. Dr. Dodson holds a Doctor of Pharmacy degree from Mercer University Southern School of Pharmacy and completed a postdoctoral residency at the Department of Veterans Affairs Medical Center in Nashville.
Jeff Hesselberg, Vice President, Regulatory Affairs. Mr. Hesselberg was appointed Vice President, Regulatory Affairs in May 2007. He joined GTx from ICOS Corporation, where from 1996 to May 2007 he served as Manager, Associate Director, and then Director of Regulatory Affairs. Most recently, Mr. Hesselberg worked on the successful development, launch and commercialization of Cialis® (tadalafil) for the treatment of erectile dysfunction. From 1984 to 1996, Mr. Hesselberg worked for Immunex Corporation and the Puget Sound Blood Center. Mr. Hesselberg holds a B.S. in Molecular Biology from the University of Wisconsin–Madison and a MBA from the University of Washington.
Domingo Rodriguez, M.D., Vice President, Clinical Operations. Dr. Rodriguez was appointed Vice President of Clinical Operations of GTx, Inc. in May 2008. Prior to his appointment, Dr. Rodriguez was the Director of Clinical Operations since October 2005. Dr. Rodriguez joined GTx, Inc. in November 2004 as a Regional Medical Scientist. Dr. Rodriguez has 20 years of experience in the biopharmaceutical industry. He began his career in 1987 with Bristol Myers Squibb and for almost 14 years served in various roles in sales and sales training and management. From 2001 to 2004, Dr. Rodríguez served as a Medical Director, Medical Science Liaison and District Sales Manager for ICOS Corporation. Dr. Rodriguez completed medical school in the Dominican Republic.
Christopher West, Vice President, Sales. Mr. West was appointed Vice President, Sales, in 2008. Mr. West has over 15 years of experience in pharmaceutical sales and marketing. Most recently, Mr. West was head of Sales and Marketing for Warner Chilcott Limited’s dermatology division. Earlier as Sales Director for the Eastern Region at Warner Chilcott, he directed a sales force of 165 representatives through two new product launches. Mr. West also worked at GlaxoSmithKline plc, where he was a member of marketing teams responsible for products in urology, respiratory and sexual health markets, and at Warner Lambert’s Parke-Davis division, where he held positions in sales management and sales training. He is a graduate of the United States Military Academy and holds an MBA from Duke University’s Fuqua School of Business.